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DObjectives: In proximal chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy is the
treatment of first choice. In general, medical treatment before pulmonary endarterectomy is not indicated. How-
ever, selected ‘‘high-risk’’ patients might benefit by optimization of pulmonary hemodynamics. Moreover, in pa-
tients whose surgery is delayed owing to limited medical resources, pretreatment may prevent clinical
deterioration. The primary objective of this study was to determine whether the dual endothelin-1 antagonist bo-
sentan improves pulmonary hemodynamics and functional capacity in patients with proximal chronic thrombo-
embolic pulmonary hypertension waiting for pulmonary endarterectomy.
Methods: We used an investigator-initiated, randomized, controlled single-blind study. Patients were random-
ized to receive bosentan (n ¼ 13) or no bosentan (n ¼ 12) for 16 weeks, next to ‘‘best standard of care.’’ The
primary end point was change in total pulmonary resistance. Secondary end points included changes in 6-minute
walk distance, mean pulmonary artery pressure, and cardiac index.
Results: After 16 weeks, the mean differences in change from baseline between the groups were as follows: total
pulmonary resistance 299 dynes $ s $ cm5 (P¼ .004), 6-minute walk distance 33 m (P¼ .014), mean pulmonary
artery pressure 11 mm Hg (P ¼ .005), and cardiac index 0.3 L $ min1 $ m2 (P ¼ .08). Treatment with bosentan
was safe. After pulmonary endarterectomy, 4 patients died (no-bosentan group: n¼ 3); the short-term in-hospital
postoperative clinical course was similar in both groups of patients.
Conclusions: Patients with proximal chronic thromboembolic pulmonary hypertension may benefit hemody-
namically and clinically from treatment with bosentan before pulmonary endarterectomy. Individual factors pre-
dictive of a beneficial response and whether this influences either morbidity or mortality associated with
pulmonary endarterectomy remain to be established. (J Thorac Cardiovasc Surg 2010;139:85-91)Chronic thromboembolic pulmonary hypertension (CTEPH)
results from incomplete resolution of the vascular obstruction
caused by pulmonary thromboembolism.1 CTEPH is thought
to develop in 1% to 4% of patients after acute pulmonary em-
bolism.2,3 Pulmonary hypertension early in the course of the
disease is considered the direct consequence of the loss of pul-
monary vascular bed owing to vascular obstruction. How-
ever, if left untreated, a hemodynamic and symptomatic
decline can be observed over time that appears to be related
to the development of secondary arteriopathy in the small pre-
capillary pulmonary vessels.1,4 As a consequence, prognosis
in CTEPH is poor and proportional to the degree of pulmo-
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The Journal of Thoracic and CPulmonary endarterectomy (PEA) is the therapy of choice
for patients with surgically accessible thrombi.1,6-10 In most
patients, PEA can be performed with an acceptable mortality
risk and results in clinical improvement and often near-
normalization of pulmonary hemodynamics.6,8 In the major-
ity of patients with CTEPH, medical pretreatment before
surgery is not deemed necessary. A significant proportion
of patients with CTEPH who undergo PEA, however, are
in hemodynamically unstable condition in the preoperative
period to the point that risks from surgery in general are
significantly increased.6-9 It can be hypothesized that if pul-
monary hemodynamics and right ventricular function are op-
timized, these ‘‘high-risk’’ patients will benefit frommedical
treatment before PEA.11-13 Moreover, in patients whose
operation is delayed owing to limited medical expertise or
resources, medical treatment may prevent hemodynamic
deterioration while the patient is awaiting PEA.11-13
Endothelin (ET)-1 is considered to play a role in the patho-
physiology of the secondary arteriopathy observed in patients
with CTEPH.14-16 In CTEPH patients with inoperable distal
disease, in 3 uncontrolled, open-label studies, treatment with
the dual ET-1 antagonist bosentan was associated with a
significant hemodynamic improvement and an increase in the
6-minute walk distance (6-MWD).17-19 So far, no studies in
surgically accessible, proximal CTEPH have been published.ardiovascular Surgery c Volume 139, Number 1 85
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6-MWD ¼ six-minute walk distance
BNP ¼ brain natriuretic peptide
CI ¼ cardiac index
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
ET-1 ¼ endothelin-1
mPAP ¼ mean pulmonary artery pressure
mRAP ¼ mean right atrial pressure
PEA ¼ pulmonary endarterectomy
TPR ¼ total pulmonary resistanceThe primary aim of this investigator-initiated, randomized,
controlled study was to assess whether treatment with bosen-
tan for 16 weeks improves pulmonary hemodynamics and
functional capacity in patients with proximal CTEPH who
wait for PEA. As a secondary aim, we studied whether pre-
operative treatment with bosentan is safe and also assessed




Consecutive patients with a diagnosis of symptomatic CTEPH, referred
to the AcademicMedical Center of the University of Amsterdam, were stud-
ied. Diagnosis of CTEPH and eligibility for PEA were established on the
basis of previously reported procedures and criteria.20 Diagnosis and cardio-
pulmonary hemodynamics were determined by pulmonary angiography and
right heart catheterization. As documented by echocardiography, left ven-
tricular function was normal in all patients. Coronary angiography was per-
formed in all patients older than 50 years of age and in patients older than 40
years of age if they had a history of smoking. All patients were treated for at
least 3 months with oral anticoagulants before referral.
Inclusion criteria were mean pulmonary artery pressure (mPAP) greater
than 25 mm Hg at rest, baseline 6-MWD of 150 to 500 m, and radiologic
evidence of proximal, surgically accessible CTEPH. For ethical reasons, pa-
tients in New York Heart Association class IV/IV were excluded. Patients
were also excluded if they had started or stopped any specific therapy for
pulmonary arterial hypertension within 1month before screening. The study
was conducted according to the provisions of the Helsinki Declaration. The
institutional ethical committee approved the protocol, and written informed
consent was obtained from all patients.
Study Design
This was an investigator-initiated study, designed as a randomized,
controlled, single-blind trial. Patients who were considered candidates
for PEA and fulfilled the inclusion criteria were randomly assigned to
receive conventional treatment (‘‘best standard of care’’) with or without
study medication (bosentan; Tracleer; Actelion Pharmaceuticals, Allsch-
wil, Switzerland) for 16 weeks. Bosentan was prescribed according to
standard guidelines: 62.5 mg twice daily for 4 weeks, followed by 125
mg twice daily for 12 weeks. Patients were evaluated at baseline and after
4, 8, 12, and 16 weeks of therapy. Safety was assessed on each visit by
monitoring vital signs and adverse events. Liver function tests were mon-
itored every 2 weeks for the first 8 weeks and every 4 weeks thereafter.
Bosentan therapy was stopped in all patients on the day of the operation.The Journal of Thoracic and Cardiovascular SurgeOutcome Measures
The primary end point was change from baseline in total pulmonary
resistance (TPR) after 16 weeks of treatment. Secondary end points were
change in 6-MWD, mPAP, cardiac index (CI), and mean right atrial
pressure (mRAP) and, in plasma, change in the level of brain natriuretic pep-
tide (BNP) as a parameter of right ventricular function.21
Two sets of pulmonary hemodynamic measurements were determined
by an observer who was blinded to the treatment regimen: at baseline and
after 16 weeks of treatment (directly before PEA). Both catheterizations
were performed under the same steady-state conditions; acute vasoreactivity
testing using oxygen or vasoactive drugs was not performed at baseline. In
addition, postoperative hemodynamic outcome was assessed on the first or
second day after PEA, before removal of the Swan-Ganz catheter (Edwards
LifeSciences, Irvine, Calif).
TPR was chosen to compare both groups, because pulmonary capillary
wedge pressure measurements are often unreliable in the presence of prox-
imal chronic thromboembolic disease,22 and insufflation of the Swan-Ganz
catheter balloon within the pulmonary artery is contraindicated after PEA
owing to the risk of suture line disruption.
6-MWT
The 6-MWTwas performed in all patients according to the guidelines of
the American Thoracic Society,23 as previously described.24 At least two
practice walk tests were performed. All tests were supervised by a respira-
tory function technologist who was blinded to the treatment regimen.
Laboratory Analysis
From patients at rest for at least 15minutes and in the supine position, blood
was obtained from the brachiocephalic vein for plasma (ethylenediamine-
tetraacetic acid), centrifuged at 3000 rpm for 10 minutes at 4C, and subse-
quently stored at 80C until analysis. BNP was determined by an
immunoradiometric assay (Shionoria,Osaka, Japan), as previously described.25
Surgical Procedure
PEA was performed according to the protocol of the University of
California San Diego.26 PEA is performed via median sternotomy. After ini-
tiation of cardiopulmonary bypass, during deep hypothermia (20C), the
right pulmonary artery is incised where it passes the aorta to the division
of the lower lobe arteries. On the left, the incision extends from the main
pulmonary artery to the origin of the left upper lobe branch. The organized
thromboembolic material is fibrotic and adherent to the vessel wall. An
endarterectomy plane is established between the intima and the fibrotic
thromboembolic material. Subsequently, the obstructing material is grasped
with a forceps, and distal circumferential dissection is performed with an
aspirating dissector. Circulatory arrest is mandatory to ensure optimal
visibility in the presence of usually copious retrograde blood flow from a
hypertrophied bronchial circulation. The circulatory arrest period is limited
to 20 minutes, with restoration of flow between each arrest.
Statistical Analysis
Data are expressed as mean  standard deviation. Differences between
patient groups were analyzed with the 2-sided unpaired Student t test. To
study the differences in individual patients between baseline and 16 weeks,
we used the 2-sided paired Student t test. If indicated, P values were cor-
rected for multiple comparisons.RESULTS
Between July 2003 and June 2006, 54 patients were con-
sidered eligible for PEA; 26 were included in the present
study. Twenty-eight patients were excluded for the follow-
ing reasons: 6-MWD greater than 500 m (n ¼ 11); mPAPry c January 2010
TABLE 1. Clinical and hemodynamic characteristics of the two
groups at baseline
Bosentan No bosentan
Subjects, n 13 12
Demographics
Age, y 67  8 64  10
Female, n (%) 10 (71%) 8 (66%)
BSA, m2 1.96  0.22 1.89  0.19
Height, cm 167  9 168  10
Weight, kg 84  18 77  12
Resting hemodynamics
mRAP, mm Hg 14  6 10  5
mPAP, mm Hg 52  7 44  9*
PCPW, mm Hg (n) 10  3 (9) 10  3 (7)
CI, L $ min1 $ m2 2.1  0.3 2.1  0.6
TPR, dynes $ s $ cm5 1084  342 988  415
SVO2,% (n) 57  8 (12) 58  11 (11)
6-MWD, m 353  84 391  87
Neurohormones
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Dless than 25 mm Hg (n ¼ 5); lack of informed consent (n ¼
5); New York Heart Association class IV/IV (n ¼ 4); phys-
ically unable to perform 6-MWT (n ¼ 2); and use of
sildenafil at study entry (n ¼ 1). Among the 26 included
and subsequently randomized patients, 14 received bosentan
and 12 received no bosentan. All but 1 patient completed the
study. After 8 weeks of treatment, liver enzyme elevation
(6 times the upper limit of normal) developed in 1 patient
in the bosentan group. After bosentan treatment was
stopped, the enzyme levels normalized. This patient was ex-
cluded from the analyses; 6-MWD had improved from 412
to 452 m after 8 weeks. No patient had renal impairment
(serum creatinine>120 mmol/L).
Baseline clinical and hemodynamic characteristics are
summarized in Table 1. There were no statistically signifi-
cant differences between the groups, except for mPAP,
which was higher in the bosentan group. The use of oxygen
and diuretics was similar in the two groups.
BNP, pmol/mL (n) 44  45 (12) 44  52 (11)
Medication
Oxygen, n 5 4
Diuretics 13 11
Digoxin, n 2 2
Values are expressed as mean  standard deviation. 6-MWD, Six-minute walk dis-
tance; BNP, brain natriuretic peptide; BSA, body surface area; CI, cardiac index;
mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; PCWP,
pulmonary capillary wedge pressure; TPR, total pulmonary resistance; SVO2, mixed
venous oxygen saturation. *P<.05.Primary End Point
Treatment with bosentan for 16 weeks was associated
with a significant decrease in TPR (Figure 1). In contrast,
in the no-bosentan group, TPR showed a small, but nonsig-
nificant increase (Figure 1). The mean difference between
the change in the groups was 299 dynes $ s $ cm5 (95%
confidence interval: 105–493; P ¼ .004; Table 2).Secondary End Points
After 16 weeks, in the bosentan group, 6-MWD had in-
creased significantly, whereas 6-MWD in the no-bosentan
group did not change (348  86 to 379  90 m; P ¼
.003; and 391  87 to 388  95 m; P ¼ .79; respectively).
The mean difference between the change in 6-MWD was 33
m (95% confidence interval: 7–59 m; P ¼ .01; Figure 2).
Treatment with bosentan for 16 weeks was also associated
with a significant decrease in mPAP and mRAP, whereas the
CI tended to increase (Figure 1). In the no-bosentan group, af-
ter 16 weeks, no differences were observed. The levels of
plasma BNP decreased in the bosentan group from 49  42
to 31  26 pmol $ L1 (P ¼ .03). In the no-bosentan group,
no change in BNP levels was observed (47  54 and 43 
55 pmol $ L1, respectively; P ¼ .57). Between the two
groups, the mean difference between the observed changes
from baseline in mPAP was 11 mm Hg (95% confidence in-
terval: 4–19 mm Hg; P ¼ .005; Table 2). The mean differ-
ences between the changes from baseline in mRAP, CI, and
BNP, however, did not reach statistical significance (Table 2).
Between the two groups, neither the dosage of diuretics
used at the end of the study nor the change in dosage of di-
uretics between baseline and the end of the study differed.
Furthermore, a small loss of weight was observed in both
groups (bosentan group 0.55  2.9 kg and no-bosentan
group0.02  2.5 kg, respectively; P ¼ .6).The Journal of Thoracic and COutcome of PEA
Four patients declined PEA. In 21 patients (11 bosentan,
10 no bosentan) PEA was performed. Four patients died
during or after PEA. One patient in the bosentan group had
a complicated postoperative course after hemodynamically
successful PEA (post-PEA mPAP: 30 mm Hg). She died
on the 10th day of sepsis of pulmonary origin with
subsequent multiorgan failure. In the no-bosentan group, 3
patients died: 1 of peroperative massive alveolar hemorrhage
and 2 of progressive right heart failure caused by persistent
pulmonary hypertension on the third and 14th postoperative
days, respectively. Postmortem examination was performed
In the 3 patients who died in the no-bosentan group. In all
patients, next to the central organized thrombi that were
removed by PEA, in multiple subsegmental arteries,
organized chronic emboli were demonstrated as well as ab-
normalities consistent with a secondary small-vessel arterio-
pathy. In the 20 patients in whom repeat hemodynamic
studies could be obtained after the operation, PEA resulted
in a significant hemodynamic improvement: mPAP de-
creased from 50  13 to 30  11 mm Hg
(P< .0001), CI increased from 2.2  0.4 to 2.4  0.5 L $
min1 (P ¼ .09), and TPR decreased from 923  326 to
529  251 dynes $ s $ cm5 (P< .0001). Directly after
PEA, persistent or residual pulmonary hypertension (mPAP
> 25 mm Hg; range 26–55 mm Hg) was observed in 12ardiovascular Surgery c Volume 139, Number 1 87
FIGURE 1. Individual hemodynamic characteristics at baseline (0 weeks) and after 16 weeks in bosentan patients (n ¼ 13) and no-bosentan patients (n ¼
12). Within-group comparisons were made with the paired Student t test. Black dots indicate mean group values. TPR, Total pulmonary resistance; mPAP,
mean pulmonary artery pressure; mRAP, mean right atrial pressure; CI, cardiac index.
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Dpatients. Seven hadmPAPgreater than 30mmHg, 2 ofwhom
died (mPAP 48 and 55 mm Hg, respectively). Preoperative
and postoperative hemodynamic characteristics of both
groups are summarized in Table 3; individual data on TPR
are illustrated in Figure 3. Although compared with the no-
bosentan group, postoperative mean mPAP and TPR were
lower in the bosentan group, these differences did not reach
statistical significance (P ¼ .09 and P ¼ .08, respectively).88 The Journal of Thoracic and Cardiovascular SurgePostoperatively, no adverse hemodynamic effects of
preoperative ET-1 blockade were observed. Moreover, in
the patients who survived PEA, no statistically significant
differences in short-term postoperative clinical course
were observed between the bosentan and the no-bosentan
groups with respect to the duration of stay in the intensive
care unit (3.9  3.3 and 4.3  4.4 days, respectively) or
the duration of mechanical ventilation (3.1  2.6 andry c January 2010
TABLE 2. Change from baseline after 16 weeks in primary and secondary study end points
Bosentan (n ¼ 13) No bosentan (n ¼ 12) Difference (95% CI) P value
TPR, dynes $ s $ cm5 237  198 62  268 299 (105 to 493) .004
mPAP, mm Hg 7  9 5  9 11 (4 to 19) .005
CI, L $ min1 $ m2 þ0.2  0.4 0.1  0.5 0.3 (0.4 to 0.7) .08
mRAP, mm Hg 5  6 1  5 3.8 (8 to 1) .16
BNP, pmol $ L1 18  24 4  21 14 (33 to 6) .16
Values are expressed as mean  standard deviation. Differences between the treatment groups are expressed as mean change with 95% confidence intervals (95% CI). Abbre-
viations are as in Table 1.
FIGURE 2. Effect of bosentan pretreatment on exercise capacity,
expressed as the change (standard deviation) from baseline in 6-minute
walk distance (D 6MWD, m) during the study in bosentan patients (n ¼
13) and no-bosentan patients (n ¼ 12).
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observed once in both groups.
DISCUSSION
In this randomized, controlled study in patients with
proximal CTEPH, preoperative treatment with the oral
dual ET-1 receptor antagonist bosentan for 16 weeks was as-
sociated with a significant hemodynamic and functional
improvement. Treatment with bosentan was safe and was
not associated with a more complicated short-term postoper-
ative clinical course. However, individual factors predictive
of a beneficial response, and whether preoperative treatment
with bosentan influences either morbidity or mortality asso-
ciated with pulmonary endarterectomy in ‘‘high-risk’’
patients, remain to be established.
This is the first randomized, controlled study in patients
with proximal CTEPH. The concept of introducing medical
treatment as a ‘‘therapeutic bridge’’ between the CTEPH
diagnosis and PEA was initially proposed for continuous
intravenous epoprostenol.11,13,22 Although the pathogene-
sis of progression of disease in CTEPH, after the initial
event, is still unclear, ET-1 is considered to play a role
in the pathophysiology of the secondary arteriopa-
thy.1,4,14,16 In a canine model of CTEPH,15 secondary pul-
monary vascular remodeling has been demonstrated. In this
model, increased ET-1 immunoreactivity was demonstrated
in the thickened pulmonary arteries of the affected animals.
Moreover, the development of vascular remodeling in this
model could be attenuated by the administration of bosen-
tan. In patients with CTEPH, circulating ET-1 levels corre-
late with hemodynamic severity of disease,16 and
upregulation of the ET-B receptor gene in the hyperplastic
media of pulmonary arterial biopsy tissue has been demon-
strated.14 ET-B receptor activation on smooth muscle cells
is considered to contribute to vasoconstriction27 and vascu-
lar remodeling.28 The reported effects of bosentan in pa-
tients with distal, inoperable CTEPH are also in support
of a role for ET-1 in CTEPH.17-19 On the basis of the pres-
ent data, blockade of the deleterious effects of ET-1 ap-
pears also of benefit in selected patients with proximal,
operable CTEPH.
The definitive treatment for CTEPH is PEA. Primary
medical therapy and pretreatment with medical therapy
before PEA are not indicated in clinically stable patientsThe Journal of Thoracic and Cwho appear to have surgically accessible CTEPH that seems
proportionate with the degree of pulmonary hypertension.
However, selected patients with more complicated variants
of CTEPHmay benefit from preoperative medical treatment,
specifically, those in whom a more complicated postopera-
tive course is anticipated, that is, patients with signs of right
heart failure or a severely increased pulmonary vascular re-
sistance.6,8,9,11-13,29 In the present study, the condition of all
but 1 patient treated with bosentan either improved or stabi-
lized both hemodynamically and functionally. In particular,
patients with increased right atrial pressure, indicating right
heart failure, appeared to benefit. In our view, future studies
should focus on better identification of high-risk patients
who will truly benefit from medical treatment, as well as
identification of those who might in fact benefit more from
immediate surgery or referral to a highly experienced
CTEPH center. Recently, we21 have reported on the poten-
tial usefulness of plasma BNP as a noninvasive parameter
to identify patients with right heart dysfunction, known to
be a risk factor for a more complicated postoperative
course.6,8 On the basis of studies in inoperable CTEPH,
acute hemodynamic responsiveness to vasoactive com-
pounds like inhaled nitric oxide and sildenafil appears of
little value topredict longer-termhemodynamic responsiveness
on treatment. The individual hemodynamic improvement onardiovascular Surgery c Volume 139, Number 1 89
TABLE 3. Hemodynamic characteristics in patients with CTEPH who underwent PEA at inclusion in the study (t ¼ 0 weeks), at the end of the
study period (16 weeks), and postoperatively (Post-PEA)
I: 0 weeks II: 16 weeks III: Post-PEA P value I vs II P value II vs III
Bosentan group (n ¼ 11)
mPAP, mm Hg 52  8 44  13 25  16 .022 .005
CI, L $ min1 $ m2 2.1  0.4 2.3  0.4 2.5  0.5 NS NS
TPR, dynes $ s $ cm5 1099  353 834  297 432  134 .005 .005
No-bosentan group (n¼ 9)
mPAP, mm Hg 46  10 49  13 35  14 NS .005
CI, L $ min1 $ m2 2.2  0.6 2.0  0.3 2.4  0.5 NS NS
TPR, dynes $ s $ cm5 979  440 1029  345 648  313 NS .005
Values are expressed as mean  standard deviation. Statistics were performed with the Student t test with the Bonferroni correction for multiple comparisons. Abbreviations as in
Table 1. CTEPH, Chronic thromboembolic pulmonary hypertension; PEA, pulmonary endarterectomy.
Acquired Cardiovascular Disease Reesink et al
A
C
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dicted on the basis of the presence or absence of an acute
hemodynamic responsiveness.30,31 The use of bosentan
may be associated with some fluid retention. However,
neither the use of diuretics nor the weight loss observed
during the study period differed between the two groups
of patients. In our view, future studies should focus on
an objective means of better identifying high-risk patients.
Currently, outcome prediction in terms of mortality and
risk for a complicated postoperative course is a subjective
one, requiring a substantial experiential base.
In the present study, treatment with bosentan was safe and
was not associated with a more complicated short-term post-
operative clinical course. In general, postoperative hemody-
namic outcome in this series was good. After PEA, no
adverse hemodynamic effects of ET-1 blockade were ob-
served; patients pretreated with bosentan even tended to
have a better hemodynamic outcome after PEA than did
the no-bosentan group. In addition, the mean durations of
stay in the intensive care unit and mechanical ventilation
were similar in both groups. Four patients died, 2 of progres-
sive right ventricular failure caused by severe postoperative
persistent pulmonary hypertension. Persistent pulmonary
hypertension after unsuccessful PEA is known to be associ-
ated with a highly increased mortality.6,8 Forty-eight of 54
patients with CTEPH who were eligible for PEA underwent
surgery, with an overall mortality of 8.3%. At present, after
more than 100 PEA procedures, the overall mortality in ourFIGURE 3. Total pulmonary resistance (TPR) in patients operated on for chroni
at the end of the study period (16 wks), and postoperatively (post-PEA).Bosentan
Bonferroni correction for multiple comparisons. *P< .05. yPatients who died. P
90 The Journal of Thoracic and Cardiovascular Surgecenter is around 8%. Whether medical treatment before
PEA in patients with CTEPH will result in a better survival
cannot be determined on the basis of the present data. In the
present study, bosentan was stopped immediately after the
operation. In view of the effectiveness and safety observed
in the present study, future studies should also focus on
the role of bosentan in the postoperative phase in high-risk
patients with CTEPH known to be at greater risk for hemo-
dynamic instability and right heart failure after PEA.
A number of study limitations can be recognized. First,
the study was open label, with the patients knowing
whether they received bosentan or not. To minimize pos-
sible confounding by the open-label design, we chose TPR
as the primary end point, and the cardiologist performing
the catherization was blinded to the treatment regimen. In
addition, the respiratory function technologist performing
the 6-MWT was also blinded to medication status. How-
ever, patients who know they are included in an active
treatment program are more likely to perceive improve-
ment and therefore try harder to improve their 6-MWD.
In view of the steady increase in 6-MWD observed during
the course of the study, which is in line with previous ob-
servations in placebo-controlled trials in patients with pul-
monary hypertension,32,33 this does not appears a likely
explanation for the improvement observed. Second, pa-
tients were selected on the basis of 6-MWD. Recently,
we24 demonstrated that 6-MWD correlates with severity
of disease in patients with CTEPH. By including onlyc thromboembolic pulmonary hypertension at inclusion in the study (0 wks),
group (n¼ 11); no-bosentan group (n¼ 9). P values were corrected with the
EA, Pulmonary endarterectomy.
ry c January 2010
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lect patients with more severe CTEPH and more compro-
mised hemodynamics. However, we may also have
excluded younger patients who walked relatively long dis-
tances, and we may have included older patients who had
less compromised hemodynamics, but whose 6-MWD was
in part limited by physical conditions unrelated to
CTEPH.34
In conclusion, in the present study, treatment with bosen-
tan was safe and associated with a significant hemodynamic
and functional improvement. On the basis of our observa-
tions, we suggest that bosentan may be of use to optimize
the treatment of selected patients with severe pulmonary hy-
pertension at risk for postoperative mortality or a more com-
plicated postoperative course.
Future studies should focus on a better identification of
patients who will benefit most from medical pretreatment
and assess whether preoperative treatment with bosentan in-
fluences either morbidity or mortality associated with pul-
monary endarterectomy in these patients.
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